Sivifene

DB05686InvestigationalSmall molecule

Investigated for use/treatment in cervical dysplasia/cancer, genital warts, and skin cancer.

Chemical structure of Sivifene
Primary indication
Investigated for use/treatment in cervical dysplasia/cancer, genital warts, and skin cancer.Curator reviewed
Formula / weight
C19H14N4O6 · 394.343 g/mol (avg)
Code names
A-007

Resolves to

Compound
UNIIXAV05295I5CAS2675-35-6ChEMBLCHEMBL307697
Structure
InChIKeyYOQPCWIXYUNEET-UHFFFAOYSA-NSMILESOC1=CC=C(C=C1)C(=NNC1=CC=C(C=C1[N+]([O-])=O)[N+]([O-])=O)C1=CC=C(O)C=C1

What you can answer from here — as of February 21, 2021

2Clinical trialsPhase, status and sponsor resolved per trial
Sign in

Which companies are running trials of Sivifene, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In